Footonomics by Jakobsen & Garnry #2 Footonomics by Jakobsen & Garnry #2 Footonomics by Jakobsen & Garnry #2

Footonomics by Jakobsen & Garnry #2

Equities 5 minutes to read
Peter Garnry

Chief Investment Strategist

Summary:  Today's Footonomics is about Denmark vs Finland which are playing the first match in group B. Denmark wins on macro with a superior Misery Index - it is wonderful to be a Dane after all. On equities the match is between Novo Nordisk and Neste, which the Danish pharmaceutical company wins 2-1 on better equity fundamentals despite Neste being a high quality oil refiner. Steen's and Peter's prediction is that Denmark wins 1-0 over Finland.


Match: Denmark vs Finland

Macro: Danish Dynamite vs. Finnish Sisu

  • Denmark has clear win on the Misery Index (CPI + Unemployment + Budget deficit) with the low score of 8.3 vs. Finlands 13.7. Unemployment being the big difference.
  • Denmark is ranked 51st in GDP globally vs. Finland 57th. A draw.

  • Denmark has most losses in the European Championship at 14 (Whaaaaaat….) vs. Finlands 1st ever Championship. Congratulations. Finland win as the 1st Championship is amazing result.

  • Best football quotes: Denmark. Richard Møller Nielsen, the winning 1992 national coach: “..We must screw down the expectations. We change our tactic and play with long balls” vs. Finland. “Jari Litmanen should be made compulsory” Ron Atkinson. How can you beat..” long balls??… Denmark win.

Equities: Novo Nordisk vs Neste

  • Novo Nordisk, the world’s largest insulin maker, wins 2-1 over Neste, one of Europe’s largest oil refiners, as the Danish pharmaceutical company is cheaper on valuation (22.9 vs 25.4 on 24-month forward P/E ratio) and has a better return on equity (75.9% vs 23.3%). Neste scores a goal on a slightly higher expected growth rate (9.0% vs 8.1%). Neste is one of the highest quality companies in Europe but battling another high quality company is just a tough match.

  • Novo Nordisk has been riding the diabetes disease for decades with the Chinese looking to be the next growth leg. A recent spinoff of the company’s insulin drugs is a new weight loss drug that has just got FDA approval based on trials showing 15% weight reduction, which according to Obesity Medicine Association is a “game changer”.

  • Neste has performed outstanding over the past decade lifting operating margins from around 5% to around 17% today. Recently the refiner has taking the lead on renewable diesel and jet fuel as the refiner is transitioning its business towards the green transformation.

Quarterly Outlook 2024 Q3

Sandcastle economics

01 / 05

  • Macro: Sandcastle economics

    Invest wisely in Q3 2024: Discover SaxoStrats' insights on navigating a stable yet fragile global economy.

    Read article
  • Bonds: What to do until inflation stabilises

    Discover strategies for managing bonds as US and European yields remain rangebound due to uncertain inflation and evolving monetary policies.

    Read article
  • Equities: Are we blowing bubbles again

    Explore key trends and opportunities in European equities and electrification theme as market dynamics echo 2021's rally.

    Read article
  • FX: Risk-on currencies to surge against havens

    Explore the outlook for USD, AUD, NZD, and EM carry trades as risk-on currencies are set to outperform in Q3 2024.

    Read article
  • Commodities: Energy and grains in focus as metals pause

    Energy and grains to shine as metals pause. Discover key trends and market drivers for commodities in Q3 2024.

    Read article
Disclaimer

Saxo Capital Markets (Australia) Limited prepares and distributes information/research produced within the Saxo Bank Group for informational purposes only. In addition to the disclaimer below, if any general advice is provided, such advice does not take into account your individual objectives, financial situation or needs. You should consider the appropriateness of trading any financial instrument as trading can result in losses that exceed your initial investment. Please refer to our Analysis Disclaimer, and our Financial Services Guide and Product Disclosure Statement. All legal documentation and disclaimers can be found at https://www.home.saxo/en-au/legal/.

The Saxo Bank Group entities each provide execution-only service. Access and use of Saxo News & Research and any Saxo Bank Group website are subject to (i) the Terms of Use; (ii) the full Disclaimer; and (iii) the Risk Warning in addition (where relevant) to the terms governing the use of the website of a member of the Saxo Bank Group.

Saxo News & Research is provided for informational purposes, does not contain (and should not be construed as containing) financial, investment, tax or trading advice or advice of any sort offered, recommended or endorsed by Saxo Bank Group and should not be construed as a record of our trading prices, or as an offer, incentive or solicitation for the subscription, sale or purchase in any financial instrument. No representation or warranty is given as to the accuracy or completeness of this information. All trading or investments you make must be pursuant to your own unprompted and informed self-directed decision. No Saxo Bank Group entity shall be liable for any losses that you may sustain as a result of any investment decision made in reliance on information on Saxo News & Research.

To the extent that any content is construed as investment research, such content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, would be considered as a marketing communication.

None of the information contained here constitutes an offer to purchase or sell a financial instrument, or to make any investments.Saxo Capital Markets does not take into account your personal investment objectives or financial situation and makes no representation and assumes no liability as to the accuracy or completeness of the information nor for any loss arising from any investment made in reliance of this presentation. Any opinions made are subject to change and may be personal to the author. These may not necessarily reflect the opinion of Saxo Capital Markets or its affiliates.

Please read our disclaimers:
- Full Disclaimer (https://www.home.saxo/en-au/legal/disclaimer/saxo-disclaimer)
- Analysis Disclaimer (https://www.home.saxo/en-au/legal/analysis-disclaimer/saxo-analysis-disclaimer)
- Notification on Non-Independent Investment Research (https://www.home.saxo/legal/niird/notification)

Saxo Capital Markets (Australia) Limited
Suite 1, Level 14, 9 Castlereagh St
Sydney NSW 2000
Australia

Contact Saxo

Select region

Australia
Australia

The Saxo trading platform has received numerous awards and recognition. For details of these awards and information on awards visit www.home.saxo/en-au/about-us/awards

Saxo Capital Markets (Australia) Limited ABN 32 110 128 286 AFSL 280372 (‘Saxo’ or ‘Saxo Capital Markets’) is a wholly owned subsidiary of Saxo Bank A/S, headquartered in Denmark. Please refer to our General Business Terms, Financial Services Guide, Product Disclosure Statement and Target Market Determination to consider whether acquiring or continuing to hold financial products is suitable for you, prior to opening an account and investing in a financial product.

Trading in financial instruments carries various risks, and is not suitable for all investors. Please seek expert advice, and always ensure that you fully understand these risks before trading. Saxo Capital Markets does not provide ‘personal’ financial product advice, any information available on this website is ‘general’ in nature and for informational purposes only. Saxo Capital Markets does not take into account an individual’s needs, objectives or financial situation. The Target Market Determination should assist you in determining whether any of the products or services we offer are likely to be consistent with your objectives, financial situation and needs.

Apple, iPad and iPhone are trademarks of Apple Inc., registered in the US and other countries. AppStore is a service mark of Apple Inc.

The information or the products and services referred to on this website may be accessed worldwide, however is only intended for distribution to and use by recipients located in countries where such use does not constitute a violation of applicable legislation or regulations. Products and Services offered on this website is not intended for residents of the United States and Japan.

Please click here to view our full disclaimer.